|Min SIP Amount||₹100|
|NAV||₹336.83 (23 Jul 2021)|
|Fund Started||01 Jan 2013|
|Fund Size||₹5,447 Cr|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||9.6%|
|Divi's Laboratories Ltd.||Healthcare||Equity||9.3%|
|Sun Pharmaceutical Industries Ltd.||Healthcare||Equity||9.1%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||8.0%|
|Gland Pharma Ltd.||Healthcare||Equity||6.6%|
|Fortis Healthcare Ltd.||Healthcare||Equity||5.5%|
|Cadila Healthcare Ltd.||Healthcare||Equity||4.7%|
|Apollo Hospitals Enterprise Ltd.||Healthcare||Equity||4.6%|
Nippon India Pharma Fund Direct Growth is a Equity Mutual Fund Scheme launched by Nippon India Mutual Fund. This scheme was made available to investors on 01 Jan 2013. Sailesh Raj Bhan is the Current Fund Manager of Nippon India Pharma Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹5,447 Cr and the Latest NAV as of 23 Jul 2021 is ₹336.83.
The Nippon India Pharma Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to 100. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 month.
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.